Protein tyrosine phosphatase receptor type C isoform CD45RC (CD45RC) (CD45RC)

Protein tyrosine phosphatase receptor type C isoform CD45RC (CD45RC) is a specific splice variant of the PTPRC gene, which encodes the leukocyte common antigen (UniProt P08575). This isoform is characterized by the inclusion of exon 6 (C) and is expressed on the surface of various immune cells, including subsets of T cells, B cells, and NK cells (PubMed: 26855131). CD45RC expression levels serve as a critical biomarker for T-cell function; high expression (CD45RC-high) identifies potent effector T cells and precursors of Th1 cells, whereas low expression (CD45RC-low) is associated with regulatory T cells (Tregs) (PubMed: 31164415). Therapeutically, CD45RC is targeted using monoclonal antibodies, such as AB1-GB, to selectively deplete effector populations while sparing or expanding Tregs to induce immune tolerance (Frontiers in Immunology, 2019). This selective approach is particularly relevant in the treatment of graft-versus-host disease (GVHD) and organ transplant rejection, where it aims to prevent immune attack without the side effects of global immunosuppression (Journal of Clinical Investigation, 2016). By modulating the signaling threshold of the T-cell receptor through its phosphatase activity, CD45RC plays a pivotal role in maintaining the balance between immune activation and suppression.

Other names

PTPRCCD45Leukocyte common antigenLCAT200Ly-5B220

Selective depletion of CD45RC-high effector T cells and B cells via antibody-dependent cellular cytotoxicity (ADCC) or apoptosis, while preserving CD45RC-low regulatory T cells to restore immune homeostasis (PubMed: 26855131).